

INSIGHTS OF THE FUTURE now

We're coming for you, cancer.



FOUNDATION
MEDICINE®



AVENIO Tumor Tissue CGP Kit V2

Backed by the trusted expertise and proven technology of Roche and Foundation Medicine®.


The AVENIO Tumor Tissue CGP Kit V2 enables labs to implement in-house comprehensive genomic profiling (CGP) with a panel aligned with the FoundationOne® CDx panel design and an integrated end-to-end 5-day research workflow from DNA extraction through secondary analysis with the FoundationOne® Analysis Platform.




From DNA extraction
to result generation in
5 days^{2,3}



Detects 4 genomic
alterations (InDels, REs,
CNAs and SNVs)^{2,3}




Assesses 4 complex
genomic signatures
(TMB, MSI, gLOH, and the
newly added HRDsig)^{2,3}



Integrated end-to-end
workflow solution^{2,3}

FoundationOne® Analysis Platform



- Thoroughly validated variant calling knowledgebase, built on insights from Foundation Medicine's experience in delivering over 1.3 million CGP reports.¹
- Broad genomic coverage identifies all four types of genomic variants including Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, and Rearrangements.^{2,3}
- 14+ QC metrics, including median coverage and potential contamination, used to assess data quality.³
- Web application for download of analysis output files (VCF, JSON, CSV, BAM)

Roche offers an extensive CGP portfolio which includes the AVENIO Tumor Tissue CGP Kit V2 and **navify**® Mutation Profiler software.

Please visit sequencing.roche.com/aveniocgpkit or contact your local Roche Sequencing representative for more information.

AVENIO Tumor Tissue CGP Kit V2 is for Research Use Only. Tertiary analysis with **navify**® Mutation Profiler is not sold as part of the AVENIO Tumor Tissue CGP Kit V2. **navify**® Mutation Profiler is CE-IVDR in Europe and for Research Use Only, not for use in diagnostic procedures in the US and other countries when used with the AVENIO Tumor Tissue CGP Kits.

References:

1. Foundation Medicine Biopharma services. Available at: <https://www.foundationmedicine.com/info/biopharma-overview> (Accessed July 2024).
2. Choi et al. Evolution of a Comprehensive Genomic Profiling (CGP) Kit to Simplify Workflows and Detect Homologous Recombination Deficiency. Poster presented at Association of Molecular Pathology Europe, June 2024. https://medically.roche.com/global/en/oncology/amp-eu-2024/medical-material/AMP-EU-2024-poster-zhang-evolution-of-a-comprehensive-pdf.html?utm_source=brochure_pdf&utm_medium=qr-code&utm_campaign=avenio-cgp_v2&utm_id=DIA-00288-24-P0090&utm_content=product_info
3. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use June 2024.

CGP, comprehensive genomic profiling. InDels, insertions and deletions. CNAs, copy number alterations. SNVs, single nucleotide variants. TMB, tumor mutational burden. MSI, microsatellite instability. gLOH, genomic loss of heterozygosity. HRDsig, homologous recombination deficiency signature. QC, quality control. REs, Rearrangements.


AVENIO and NAVIFY are registered trademarks of Roche. FoundationOne® and Foundation Medicine are registered trademarks of Foundation Medicine, Inc.

AVENIO Tumor Tissue CGP Kit V2
Powered by **FOUNDATION MEDICINE**

navify® Mutation Profiler

Cloud-based tertiary analysis for any Next Generation Sequencing (NGS) assay or platform

Streamline your interpretation, annotation and reporting of oncology sequencing data with an intuitive interface and the comprehensive Roche knowledge base – with access to targeted therapies and clinical trials – for personalized medicine studies



Reduces time to report with its easy-to-use interface



Secured – ISO, HIPAA and GDPR-EU compliant system



Enables shared lab analytics and variant classification



Option to share and access anonymized data to aid in analysis



Customizable content and reports



Integrates with institutional information systems

The Roche knowledge base:

- Provides in-depth, up-to-date content curation for:
 - Many panels on the market, including the 335-gene AVENIO Tumor Tissue CGP Kit V2
 - gLOH, TMB, MSI, HRDsig¹
- Offers access to clinical trial information for >140 countries²
- Informs on implications of variant combinations for characterizing disease¹
- Undergoes a rigorous, multi-step data quality curation process¹

Roche offers an extensive CGP portfolio of flexible solutions which includes **navify®** Mutation Profiler software and the AVENIO Tumor Tissue CGP Kit V2 for in-house comprehensive genomic profiling.

Please visit navify.com/products/navify-mutation-profiler or contact your local Roche Sequencing representative for more information.

AVENIO Tumor Tissue CGP Kit is for Research Use Only. Not for use in diagnostic procedures. In the US, **navify®** Mutation Profiler is for Research Use Only. Not for use in diagnostic procedures.

References:

1. **navify®** Mutation Profiler v2.6 Instructions for Use June 2024.

2. **navify®** Mutation Profiler v2.6 - User Assistance v2.5 Manual.

ISO, International Organization for Standardization. CGP, comprehensive genomic profiling. HIPAA, Health Insurance Portability and Accountability Act. GDPR-EU, General Data Protection Regulation European Union. gLOH, genomic Loss of Heterozygosity. TMB, Tumor Mutational Burden. MSI, Microsatellite Instability. HRDsig, Homologous Recombination Deficiency Signature

© 2024 F. Hoffmann-La Roche Ltd. AVENIO and NAVIFY are trademarks of Roche. MC-17471 August 2024